# Podcasters, Presidents, and Psychedelics: How Joe Rogan Got Trump Into Ibogaine > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ibogaine-addiction-treatment-psychedelic-research-update/ > **Published:** 2026-04-19T07:04:45-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:18:10-04:00 > **Clinical Summary:** Explore ibogaine addiction treatment and its emerging role in psychedelic research, safety protocols, and policy developments. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Psychedelics[Addiction Medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/)PtsdPolicyVeterans Why This Matters Presidential endorsement of specific psychedelic compounds could accelerate research funding and regulatory pathways, potentially impacting veteran access to experimental treatments. This political development may influence FDA scheduling decisions and clinical trial priorities for ibogaine, a compound with limited but promising preliminary data for [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). Clinical Summary Ibogaine, derived from the African shrub Tabernanthe iboga, has shown preliminary efficacy for opioid and stimulant addiction in small studies, likely through its action on multiple neurotransmitter systems including dopamine and serotonin. The compound carries significant cardiac risks, including QT prolongation and potential fatal arrhythmias, requiring intensive medical monitoring. Current evidence consists primarily of observational studies and case reports from international treatment centers, with limited controlled trial data in the United States due to Schedule I classification. Dr. Caplan’s Take “Political enthusiasm doesn’t change the fundamental clinical reality: ibogaine requires rigorous safety protocols and careful patient selection. I need robust phase III data before recommending any psychedelic to patients, regardless of who’s promoting it.” Clinical Perspective 🧠 Clinicians should anticipate increased patient inquiries about ibogaine following political attention, requiring education about current evidence limitations and safety concerns. Any future therapeutic use will likely require specialized cardiac monitoring and contraindication screening. The political momentum may accelerate legitimate research, but patient safety standards must remain unchanged regardless of advocacy source. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Podcasters%2C%20Presidents%2C%20and%20Psychedelics%3A%20How%20Joe%20Rogan%20Got%20Trump%20Into%20Ibogaine%20%40drcaplan&url=https%3A//www.motherjones.com/politics/2026/04/podcaster-joe-rogan-trump-executive-order-ibogaine-psychedelics-therapy-ptsd-veterans-depression/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.motherjones.com/politics/2026/04/podcaster-joe-rogan-trump-executive-order-ibogaine-psychedelics-therapy-ptsd-veterans-depression/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Podcasters%2C%20Presidents%2C%20and%20Psychedelics%3A%20How%20Joe%20Rogan%20Got%20Trump%20Into%20Ibogaine%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.motherjones.com/politics/2026/04/podcaster-joe-rogan-trump-executive-order-ibogaine-psychedelics-therapy-ptsd-veterans-depression/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.motherjones.com/politics/2026/04/podcaster-joe-rogan-trump-executive-order-ibogaine-psychedelics-therapy-ptsd-veterans-depression/](https://www.motherjones.com/politics/2026/04/podcaster-joe-rogan-trump-executive-order-ibogaine-psychedelics-therapy-ptsd-veterans-depression/) Table of Contents - [FAQ](#FAQ)[What type of clinical development is this article about?](#What_type_of_clinical_development_is_this_article_about) - [What medical conditions are relevant to this news?](#What_medical_conditions_are_relevant_to_this_news) - [Are psychedelics currently approved for medical use?](#Are_psychedelics_currently_approved_for_medical_use) - [What policy implications does this news have?](#What_policy_implications_does_this_news_have) - [Why is this considered clinically relevant?](#Why_is_this_considered_clinically_relevant) - [Related](#Related) ## FAQ #### What type of clinical development is this article about? This article discusses emerging findings or policy developments in psychedelics and [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/) that are worth monitoring closely. It has been classified as having “Notable Clinical Interest” by CED Clinical Relevance. #### What medical conditions are relevant to this news? The article focuses on [PTSD treatment](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) and addiction medicine applications. These represent key therapeutic areas where psychedelics are showing clinical promise. #### Are psychedelics currently approved for medical use? Psychedelic treatments are still largely in development phases, with most requiring further [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and regulatory approval. Current medical applications are limited and typically available only through [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) or specialized programs. #### What policy implications does this news have? The article suggests there are emerging policy developments related to psychedelic medicine that clinicians should monitor. These policy changes could affect future treatment availability and regulatory pathways for psychedelic therapies. #### Why is this considered clinically relevant? This news has been rated as having notable clinical interest because psychedelics represent a potentially transformative approach to treating PTSD and addiction. The emerging findings could significantly impact future treatment protocols and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) options. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental …](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/) Learn about the executive order signed by Trump to speed up legal access to psychedelic treatments for mental health patients. [Read More](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/) [Trump signs order to accelerate access to psychedelic drug treatments – Reuters](https://cedclinic.com/psychedelic-drug-treatments-policy-accelerate-access-trump/) An overview of Trump's order aimed at accelerating access to psychedelic drug therapies and its implications. [Explore Details](https://cedclinic.com/psychedelic-drug-treatments-policy-accelerate-access-trump/) [Trump psychedelics order largely symbolic, analysts say – The Guardian](https://cedclinic.com/psychedelic-executive-order-impact-research-policy/) Analysis of the symbolic nature of Trump's psychedelics order and its potential impact on research and policy. [Learn More](https://cedclinic.com/psychedelic-executive-order-impact-research-policy/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).